337 related articles for article (PubMed ID: 17885587)
21. Dendritic cell vaccines in metastasized malignant melanoma.
Erdmann M; Schuler-Thurner B
G Ital Dermatol Venereol; 2008 Aug; 143(4):235-50. PubMed ID: 18833080
[TBL] [Abstract][Full Text] [Related]
22. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
24. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients.
Torisu-Itakura H; Lee JH; Huynh Y; Ye X; Essner R; Morton DL
J Immunother; 2007; 30(8):831-8. PubMed ID: 18049335
[TBL] [Abstract][Full Text] [Related]
25. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.
Tagawa ST; Cheung E; Banta W; Gee C; Weber JS
Cancer; 2006 Mar; 106(6):1353-7. PubMed ID: 16475151
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol; 2008 Dec; 35(12):801-3. PubMed ID: 19239565
[No Abstract] [Full Text] [Related]
27. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration.
Müller-Berghaus J; Ehlert K; Ugurel S; Umansky V; Bucur M; Schirrmacher V; Beckhove P; Schadendorf D
Cancer Res; 2006 Jun; 66(12):5997-6001. PubMed ID: 16778169
[TBL] [Abstract][Full Text] [Related]
28. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
29. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
30. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
31. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
32. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
[TBL] [Abstract][Full Text] [Related]
33. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli M; Ferrone S
Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of immunotherapy in the treatment of melanoma.
Faries MB
Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of malignant melanoma.
Kadison AS; Morton DL
Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
[TBL] [Abstract][Full Text] [Related]
36. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
Brostjan C; Bayer A; Zommer A; Gornikiewicz A; Roka S; Benkö T; Yaghubian R; Jakesz R; Steger G; Gnant M; Friedl J; Stift A
Cancer; 2003 Nov; 98(10):2291-301. PubMed ID: 14601101
[TBL] [Abstract][Full Text] [Related]
39. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
40. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]